Assays for predicting and monitoring responses to lung cancer immunotherapy-中国期刊网

摘要 Immunotherapyhasbecomeakeystrategyforcancertreatment,andtwoimmunecheckpoints,namely,programmedcelldeath1(PD-1)anditsligand(PD-L1),haverecentlyemergedasimportanttargets.TheinteractionblockadeofPD-1andPD-L1demonstratedpromisingactivityandantitumorefficacyinearlyphaseclinicaltrialsforadvancedsolidtumorssuchasnon-smallcelllungcancer(NSCLC).ManycelltypesinmultipletissuesexpressPD-L1aswellasseveraltumortypes,therebysuggestingthattheligandmayplayimportantrolesininhibitingimmuneresponsesthroughoutthebody.Therefore,PD-L1isacriticalimmunomodulatingcomponentwithinthelungmicroenvironment,butthecorrelationbetweenPD-L1expressionandprognosisiscontroversial.MoreevidenceisrequiredtosupporttheuseofPD-L1asapotentialpredictivebiomarker.ClinicaltrialshavemeasuredPD-L1intumortissuesbyimmunohistochemistry(IHC)withdifferentantibodies,buttheassessmentofPD-L1isnotyetstandardized.Somecommercialantibodieslackspecificityandtheirreproducibilityhasnotbeenfullyevaluated.FurtherstudiesarerequiredtoclarifytheoptimalIHCassayaswellastopredictandmonitortheimmuneresponsesofthePD-1/PD-L1pathway.

1Jean G. Bustamante Alvarez;Maria Gonzalez-Cao;Niki Karachaliou;Mariacarmela Santarpia;Santiago Viteri;Cristina Teixido;Rafael Rosell. Advances in immunotherapy for treatment of lung cancer.肿瘤,2015-03.
2Xu Yang,Chen Liang-An. Lung cancer treatment in the era of immunotherapy.医药卫生,2020-11.
3Zhu Hao-Hua,Feng Yu,Hu Xing-Sheng. Emerging immunotherapy targets in lung cancer.医药卫生,2020-11.
4Zhou Fei,Zhou Cai-Cun. Immunotherapy in non-small cell lung cancer: advancements and challenges.医药卫生,2021-05.
5Luo Wen-Xin,Yang Lan,Li Wei-Min. Immunotherapy-related toxicity in lung cancer: clinical characteristics and managing strategy.医药卫生,2021-04.
6Li Chu-Ling,Song Yong. Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges.医药卫生,2021-09.
7Fajiu Li,Ying Chen,Juanjuan Wu,Chenghong Li,Shi Chen,Ziyang Zhu,Wei Qin,Min Liu,Bingzhu Hu,Shuang Liu,Wenzhao Zhong. The earlier, the better? A review of neoadjuvant immunotherapy in resectable non-small-cell lung cancer.医药卫生,2022-12.
8Shi Wen-Jia,Zhao Wei. Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective.医药卫生,2020-11.
9Li Rui-Yu,Liang Zhi-Yong. Circulating tumor DNA in lung cancer: real-time monitoring of disease evolution and treatment response.医药卫生,2020-11.
10JianmeiHou LingTian YuquanWei. Cancer Immunotherapy of Targeting Angiogenesis.免疫学,2004-03.

Assays for predicting and monitoring responses to lung cancer immunotherapy

来源期刊

相关推荐

同分类资源更多

相关关键词

Assays for predicting and monitoring responses to lung cancer immunotherapy

来源期刊

相关推荐

同分类资源 更多

相关关键词

同分类资源更多